Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study
Javier Garciá Corbacho(Breast Cancer Research Foundation), Francesco Schettini(Breast Cancer Research Foundation), Begoña Mellado(Hospital Clínic de Barcelona), Lydia Gaba(Hospital Clínic de Barcelona), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Iván Victoria(Hospital Clínic de Barcelona), Òscar Reig(Hospital Clínic de Barcelona), Azucena E. González Navarro(Hospital Clínic de Barcelona), Joan Maurel(Breast Cancer Research Foundation), Neus Basté(Hospital Clínic de Barcelona), Núria Viñolas(Hospital Clínic de Barcelona), Miquel Nogué(Hospital General de Granollers), Patricia Galván(Vall d'Hebron Institute of Oncology), Manel Juan(Hospital Sant Joan de Déu Barcelona), Esther Sanfeliu(Hospital Clínic de Barcelona), Tamara Saurí(Hospital Clínic de Barcelona), Laura Angelats(Hospital Clínic de Barcelona), Alberto Indacochea(Hospital General de Granollers), Aleix Prat(Hospital Clínic de Barcelona), Debora Moreno(Hospital Clínic de Barcelona), Bárbara Adamo(Hospital Clínic de Barcelona), Estela Pineda(Hospital Clínic de Barcelona), Laura Mezquita(Hospital Clínic de Barcelona)
Cited by 3
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k